Análisis de la acción Moderna Inc (MRNA)MRNAModerna Inc

Moderna is not only holding up but hitting new highs while AI hardware stocks pull back. The most valuable part of AI implementation is its application in drug development, not in producing more junk short videos for cheap dopamine. The second image shares monitoring points for when Moderna's rally ends and upside targets. $MRNA

OpenAI bought an AI drug company, but not the part that designs molecules OpenAI acquired Orchestra Bio and folded it into its own life sciences project, Rosalind. This company doesn't touch molecule generation; what it does looks quite traditional: using AI agents to help drugmakers track trial scheduling and clinical progress, and coordinate manufacturing delays. The official announcement says: a new drug still takes an average of 10 to 15 years. When large model companies enter pharma, the first thing they take on isn't science, it's operations. 1. Who's on the team CEO Ashoka Rajendra, former head of development and manufacturing products at Benchling. - Benchling is a leader in biopharma R&D software, valued at $6.1 billion in its 2021 Series F, and officially says more than 1,300 biotech companies use it, including Merck, Moderna, and Sanofi, to record experiments, manage samples, and handle data. - He built exactly the software for the stretch where a drug goes from the lab to manufacturing. He sees most clearly where pharma companies break down and where they leak money. CTO Andy Xu, former VP of engineering at Numenta. - Numenta was founded in 2005 by Palm founder Jeff Hawkins, starting from brain science and doing AI, later focusing on making model inference faster and cheaper, officially claiming it can speed up inference by more than 10 to 100 times. - Scheduling and dispatch work runs a huge amount of inference every day; if costs can't be pushed down, it's unaffordable. One understands pharma workflows, the other understands running systems cheaply. 2. The bottleneck isn't the algorithm Molecular design has been buzzing for years, and everyone thought AI could quickly compute new drugs. But after computing them out, synthesis, animal testing, and Phase III trials can't be skipped. Trial and error in the physical world can't be replaced by algorithms. 3. Science sets the ceiling, grunt work decides survival A lot of new drug R&D time is spent on internal friction: disconnected communication between departments, scheduling delays at outsourced research organizations, and gaps when scaling up production. Straightening out this information gap between discovery and clinical trials is something agents can turn into real savings right now. I think what OpenAI wants from this investment is also an entry point and data. Tools that only run molecular models struggle to get into pharma companies' core decisions; once it takes over clinical and manufacturing scheduling, the data from pharma companies' real daily workflows passes through it. 4. Chew through the messy process work first, then aim for the scientific holy grail. Molecular design sells a lottery ticket ten-plus years out. Process coordination sells tomorrow's cash ledger. Everyone thought large models would enter pharma as Einstein first, but it turns out they went in as project managers first.

$MRNA is bouncing from daily support. If it breaks above $237.86, I think it can enter price discovery and move higher. @ShaneStoffer is going to be super wealthy.

There is still some time for some names ahead of the $MRNA presentation on Saturday... People will FOMO into these personalized treatment names — not if, but when. $TEM is one of them.

$MRNA +667% YTD. From our "2026: Outlook and Convictions" edition in January: "MRNA fits as a rebuild candidate because it captures the essence of what these cycles look like at the single-name level. The early part of a recovery is often noisy and headline-sensitive. The later part is more important: the point where the chart begins acting less like a bounce vehicle and more like a position-building environment. In a year where biotech improves, names like MRNA can become a leadership proxy because they tend to reflect whether the market is willing to carry speculative health exposure beyond a short window."